Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of …
Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of …
Gene therapy companies have been especially vulnerable to a public market downturn that’s shaken the biotech sector. But the difficult environment hasn’t stopped venture firms …
Dive Brief: Gene therapy developer Solid Biosciences is laying off 35% of its employees, announcing Wednesday a plan to extend its current funds for another …
Dive Brief: Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal disease. …
Dive Brief: Orchard Therapeutics, a London- and Boston-based developer of gene therapies, plans to lay off 30% of its workforce, or about 65 employees, as …
Bluebird bio has spent the better part of two decades developing gene therapies for rare diseases. This summer, after years of clinical trials, setbacks and …
Jeffrey Marrazzo, CEO of gene therapy developer Spark Therapeutics, will step down as head of the company he co-founded almost nine years ago, steered to …
Dive Brief: The National Health Service in England and Wales will cover treatment with an exceptionally high-priced gene therapy for a rare and fatal genetic …
Metagenomi, a biotech startup that three months ago struck a research alliance with Moderna, has raised $175 million to expand and build on its early …
Dive Brief: Sarepta Therapeutics on Monday presented new results from a placebo-controlled study of its experimental gene therapy for Duchenne muscular dystrophy, a closely watched …
The Food and Drug Administration has cleared Allogene Therapeutics to resume testing its cancer cell therapies after determining the company’s technology wasn’t to blame for …
Lengo’s drug targets a mutation in the gene that drives production of a protein called EGFR, which, in turn, can help spur tumor growth. The …
Mirati’s drug, called adagrasib, is particularly closely watched. After Lumakras, which won U.S. approval earlier this year, it’s the most advanced experimental drug targeting a …
Mammoth’s evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to …
UK’s innovation agency provides funding to develop advanced technologies for the manufacturing of autologous ex vivo gene therapies. Plasticell, a developer of stem cell technologies …
New therapies that may cure diseases caused by defective genes will get a faster path to approval by U.S. regulators, part of an effort by …
Celonic AG, the Swiss biologics contract development and manufacturing organization, has appointed Soenke Brunswieck as Vice President Cell & Gene Therapy to establish Celonic`s new …
Initial clinical successes with cell and gene therapies have driven significant investment in these next-generation technologies by both large bio/pharma companies and start-up specialist firms …
